Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH - CC

Contract Value

Not provided

Codes & Classification
Solicitation Number

NOI-27-000056

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
The National Institutes of Health Clinical Center (NIH-CC), located in Bethesda, Maryland, has issued a presolicitation notice (NOI-27-000056) indicating its intent to procure Sirturo (Bedaquiline) tablets through a sole source arrangement with Cardinal Health (DBA Metro Medical Supply). This acquisition is governed by the statutory authority 41 U.S.C. 1901 (a)(1) as implemented by FAR 13.106-1, which allows for sole source procurement when only one responsible source exists and no other supply or service will satisfy agency requirements. Purpose and Scope: The NIH Clinical Center is a premier clinical research hospital that provides comprehensive medical services to patients participating in NIH human research protocols. The CC Pharmacy department is tasked with ensuring the availability of essential medications for both inpatient and outpatient clinical trial participants. The current procurement activity is focused on acquiring Sirturo (Bedaquiline) tablets, a critical pharmaceutical used in patient care for specific clinical protocols. Sirturo is available in two formulations: 100 mg tablets in 188-count bottles (NDC# 59676070101) and 20 mg tablets in 60-count bottles (NDC# 59676070260). The anticipated annual requirement ranges from 12 to 36 bottles of each type, based on historical usage and projected patient enrollment. Key Requirements and Deliverables: The primary deliverables for this procurement are the specified quantities of Sirturo (Bedaquiline) tablets in the aforementioned formulations. Delivery is expected within 30 days of contract award or as mutually agreed upon by the parties. The medication must be supplied in the exact forms and quantities required by the NIH-CC Pharmacy department to ensure uninterrupted patient care and support ongoing clinical research activities. Justification and Special Considerations: Sirturo (Bedaquiline) is a unique medication with no available substitutes. Janssen Therapeutics, the manufacturer, has designated Cardinal Health/Metro Medical Supply as the sole authorized distributor in the United States. Previous market research and competitive solicitations, including RFQ-CC-24-008485, have confirmed that Cardinal Health/Metro Medical is the only vendor capable of fulfilling this requirement. No other companies responded to prior solicitations, reinforcing the necessity for a sole source procurement. This ensures compliance with regulatory requirements and guarantees the authenticity and quality of the medication supplied. Contracting Entity and Classification: The contracting entity for this procurement is the National Institutes of Health Clinical Center, a federal office under the Department of Health and Human Services. The procurement is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505 (Drugs and Biologicals). The place of performance and delivery is the NIH Clinical Center in Bethesda, Maryland. Procurement Type and Response Instructions: This notice is a presolicitation and not a request for proposal. The procurement will be conducted on an other than full and open competition basis, specifically as a sole source requirement. Interested parties who believe they can meet the requirements are invited to submit a capability statement referencing NOI-27-000056 by 4:00 PM Eastern Standard Time on November 11, 2026, to Lu Chang at [email protected]. All responses received by the closing date will be considered, but the final determination to compete or proceed with the sole source award rests solely with the government. Constant Elements: Throughout the contract lifecycle, the requirement for Sirturo (Bedaquiline) tablets in specified formulations and quantities, the sole source relationship with Cardinal Health/Metro Medical Supply, and the delivery location at the NIH Clinical Center in Bethesda, Maryland, will remain unchanged. The procurement will continue to be governed by federal regulations and NIH-CC’s commitment to supporting clinical research and patient care. For further information, contractors may refer to the official notice on SAM.gov (Opportunity ID: 60c6fdeb7763436d9e2ac65227d95af1) or contact the primary point of contact, Lu Chang, via email. This opportunity is highly specialized and limited to authorized distributors of Sirturo (Bedaquiline), making it suitable only for entities with direct access to the manufacturer’s supply chain and the ability to meet NIH-CC’s stringent requirements for pharmaceutical procurement.